Breast Cancer (BC) has surpassed lung cancer as the leading cause of cancer incidence in the world, with an estimated 2.3 million new cases, representing 11.7% of all cancer cases, with women bearing the brunt of it.In India, as per Globocan 2020 data, BC accounted for 13.5% (178,361) of all cancer cases and 10.6% (90,408) […]
Sapien has been actively collecting FFPE blocks, blood and data from #breastcancer patients in India. With over 18,000 Indian breast cancer cases from 9 cancer hospitals, Sapien has collated demographic and diagnostic datasets to aid in the fight against #breastcancer. Treatment, outcomes, genomic, biomarker and imaging data is being added to the #biobank, making early detection and optimal treatment […]
The impact of two driver mutations of RET gene, V804M/L and S891A, on Thyroid cancer was described recently by Pichardo et al in JAMA Otolaryngology, 2023. In a population screening, 75 people were identified to have 2 Pathogenic or Likely Pathogenic (P/LP) germline variants of the RET gene. 20 out of these 75 patients chose […]
Delighted to be a part of 8th Annual BGCI #conference held at the #University of Hyderabad from July 7th to 9th, 2023 where Rakesh Sharma, PhD and Madhuri R presented posters titled “Molecular landscape of #lung adenocarcinoma in India for personalizing therapy” and “Driver gene alterations in EGFR and IDH1 are mutually exclusive in Indian Gliomas”. […]
Sapien is surveying different #tumor types in its #biobank for mismatch repair-deficiency (MMR-D), also called microsatellite instability (MSi-High). This is because #colorectalcancer #patients with MMR-D do not respond well to standard #chemotherapy but do respond to immune checkpoint inhibitors or ICI. To see which other #cancers may benefit from immune checkpoint inhibitors such as #PD1, […]
Until recently, HER2 (or ErbB2) targeting drugs were only approved for HER2-amplified breast & gastric cancers. FDA has now granted accelerated approval for trastuzumab or Enhertu to treat lung cancer patients bearing activating HER2 mutations. We analyzed our data of ~1000 solid cancer cases generated using the OncomineTM Dx NGS panel to determine the pattern […]
Our paper on first ever reported establishment of a cell culture from a rare brain tumor (DIG glioma), is published in Frontiers in Pharmacology journal, with Impact factor of 4.5. Such primary cultures are very useful for drugdevelopment and phenotypic screening.
Recent Comments